Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA On Drug Pricing: Incremental Steps, But No Full-Frontal Assault

Executive Summary

US agency will continue to avoid ‘big bold’ actions on drug pricing under the Trump Administration, industry representatives and attorneys predict, adding that easing restrictions on manufacturer communications to payers and advocating for biosimilars would help in pricing debate.

You may also be interested in...



The Latest Furor Over Trump’s Drug Pricing Plan

Did the head of the Office and Management & Budget really endorse Part D rebates? Like so much about the Trump Administration’s response to drug pricing, there is probably a lot less to the story than it sounds.

User Fee Bill Caught In Comey Firing Tidal Wave

Senate committee forced to postpone mark-up of FDA user fee reauthorization legislation; drug pricing fight may be postponed by hearing pledge.

User Fee Bill Caught In Comey Firing Tidal Wave

Senate committee forced to postpone mark-up of FDA user fee reauthorization legislation; drug pricing fight may be postponed by hearing pledge.

Related Content

Topics

UsernamePublicRestriction

Register

PS120574

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel